Thyroid function alters during neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

[1]  A. Tukiendorf,et al.  Thyroid Function after Postoperative Radiation Therapy in Patients with Breast Cancer , 2016, Asian Pacific journal of cancer prevention : APJCP.

[2]  H. Putter,et al.  Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  M. Brentani,et al.  Estrogen-Responsive Genes Overlap with Triiodothyronine-Responsive Genes in a Breast Carcinoma Cell Line , 2014, TheScientificWorldJournal.

[4]  G. Ren,et al.  Implication from thyroid function decreasing during chemotherapy in breast cancer patients: chemosensitization role of triiodothyronine , 2013, BMC Cancer.

[5]  T. Funakoshi,et al.  Risk of hypothyroidism in patients with cancer treated with sunitinib: A systematic review and meta-analysis , 2013, Acta oncologica.

[6]  J. Manjer,et al.  Triiodothyronine levels in relation to mortality from breast cancer and all causes: a population-based prospective cohort study. , 2013, European journal of endocrinology.

[7]  D. Führer,et al.  Thyroid hormone, thyroid hormone receptors, and cancer: a clinical perspective. , 2013, Endocrine-related cancer.

[8]  T. Ozpaçacı,et al.  Serum Resistin and Insulin-Like Growth Factor-1 Levels in Patients with Hypothyroidism and Hyperthyroidism , 2013, Journal of thyroid research.

[9]  J. Malm,et al.  Prospectively measured thyroid hormones and thyroid peroxidase antibodies in relation to breast cancer risk , 2012, International journal of cancer.

[10]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  F. Bladou,et al.  Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma? , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  L. Hertle,et al.  Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib , 2011, World Journal of Urology.

[13]  D. Forman,et al.  Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study , 2011, British Journal of Cancer.

[14]  P. Larsen,et al.  Thyroid dysfunction from antineoplastic agents. , 2011, Journal of the National Cancer Institute.

[15]  D. Ribatti,et al.  Thyroid hormone as a regulator of tumor induced angiogenesis. , 2011, Cancer letters.

[16]  M. lenhard,et al.  Thyroid function in breast cancer patients. , 2010, Anticancer research.

[17]  G. Beckett,et al.  Mechanisms behind the non-thyroidal illness syndrome: an update. , 2010, The Journal of endocrinology.

[18]  L. Vatten,et al.  Thyroid Function and Cancer Risk: A Prospective Population Study , 2009, Cancer Epidemiology Biomarkers & Prevention.

[19]  E. Salazar,et al.  Effects of thyroid hormones on human breast cancer cell proliferation , 2008, The Journal of Steroid Biochemistry and Molecular Biology.

[20]  L. Rybicki,et al.  Association between development of hypothyroidism and improved survival in patients with head and neck cancer. , 2006, Archives of otolaryngology--head & neck surgery.

[21]  A. D. de Craen,et al.  Thyroid status, disability and cognitive function, and survival in old age. , 2004, JAMA.

[22]  A. Hutcheon,et al.  A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. , 2003, Breast.

[23]  V. Moudgil,et al.  Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, p53 and retinoblastoma, in breast cancer cells , 2002, Oncogene.

[24]  J. Rodier,et al.  Severe hypothyroidism after chemotherapy and locoregional irradiation for breast cancer. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[25]  M. Kailajärvi,et al.  Alterations in Laboratory Test Results during Adjuvant Breast Cancer Treatment , 2000, Clinical chemistry and laboratory medicine.

[26]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Bonfrer,et al.  Primary hypothyroidism in breast cancer patients with irradiated supraclavicular lymph nodes. , 1985, British Journal of Cancer.

[28]  B. Vonderhaar,et al.  Effect of thyroid status on development of spontaneous mammary tumors in primiparous C3H mice. , 1982, Cancer research.

[29]  G. Barnett,et al.  Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study. , 2003, Anticancer research.